Platforma vs. Geneious vs. PipeBio: How to choose the best antibody discovery platform in 2026
Key considerations and a detailed comparison of the leading antibody discovery platforms
Key Considerations When Choosing an Antibody Discovery Platform
Selecting a digital backbone for your discovery pipeline is a strategic decision that directly impacts research speed, data quality, and team productivity. The following criteria help ensure that your chosen platform doesn’t just store data, but actively drives your candidates toward the clinic.
End-to-end workflow coverage: The platform should support a complete, end-to-end workflow, taking you from raw NGS and functional assay data through clonotyping, clustering, enrichment analysis, and lead selection, without the need to stitch together multiple tools or spreadsheets.
Scientist-first usability: Wet-lab scientists should be able to explore data, apply filters, and identify leads without writing scripts, managing Excel files, or relying on bioinformatics support for every iteration.
Integrated downstream decision-making: Sequence analysis alone is not enough. Look for platforms that integrate enrichment, developability metrics, liabilities, and functional assay data (e.g., ELISA, SPR) directly into lead prioritization.
Computational scalability & throughput: Modern discovery generates millions of NGS reads. Your platform must handle high-throughput sequencing data without lag, supporting massive-scale clonotyping, clustering, and filtering as your dataset grows.
Flexible deployment & data control: In IP-sensitive therapeutic discovery, maintaining full ownership and control of your data is non-negotiable. Many teams are increasingly opting for on-premise deployments to ensure full data ownership and compliance.
Built for discovery teams: Platforma
Platforma is the go-to solution for labs that need to scale without hiring a fleet of bioinformaticians. Built on MiXCR and other transparent algorithms, Platforma combines its gold-standard accuracy with rich visualizations for an end-to-end antibody discovery workflow. The software supports custom algorithms and on-premise deployment to ensure the data stays secure. Users have reported that while using Platforma, they can cut lead selection time from weeks to hours.
Geneious Biologics:
Geneious has been a staple in molecular biology for decades. Now part of the Dotmatics and Siemens ecosystem, its Biologics suite is strong for sequence annotation and visualization, but it’s primarily suited for analyzing individual sequences rather than the massive, multi-dimensional datasets generated by modern high-throughput antibody discovery. Scientists working with millions of reads may need a platform that offers scalable workflows, high-performance clustering, and interactive visualizations to accelerate lead selection and make large-scale discovery more practical.
PipeBio:
PipeBio is a cloud-based platform for antibody, TCR, and peptide sequence analysis, offering automated workflows for clonotyping, clustering, and basic lead identification. While the software promises to process tens of millions of NGS reads in hours via the cloud, users at large pharmaceutical companies have reported that the lack of an on-premise solution is a deal-breaker for their data security requirements. Researchers also frequently have to perform manual analysis via Excel sheets to bridge the gaps between disconnected outputs. This fragmentation breaks the chain of custody for data, introduces human error, and slows the transition from sequence to lead.
Enpicom:
Enpicom is a user-friendly and lightweight platform for antibody discovery, enabling scientists to analyze their Rep-Seq data through a suite of apps on its platform. However, like Pipe Bio, Enpicom is entirely cloud-based, which can pose regulatory or data sovereignty challenges for organizations that cannot transfer sensitive data outside their own borders.
Other Tools
CROs: Outsourced antibody discovery services provide end-to-end project support but often limit data ownership, control, and repeatability. When you rely on a CRO, you typically receive only the “final leads,” losing access to the raw NGS data and reproducibility insights.
Open-source tools (e.g., MiXCR): Powerful for immune repertoire analysis and supports any chemistry and species, but require command-line expertise and additional tools for downstream analysis.
Final Verdict: Why Choose Platforma
When evaluating antibody discovery platforms, teams must balance usability, performance, flexibility, and data control. While competitors like Geneious, PipeBio, and Enpicom excel in specific areas, Platforma is the only platform that delivers a truly end-to-end solution:
Complete workflow: From raw NGS and functional assay data to clonotyping, clustering, enrichment analysis, developability assessment and lead selection within a single platform
Flexible deployment & data control: Supports secure on-premise or private cloud deployment, meeting strict data sovereignty requirements.
Built for scientists: A user-friendly interface that eliminates the need for any manual intervention or Excel files.
High-performance handling of large datasets: Efficiently manages millions of clonotypes, and rounds of enrichment without workflow slowdowns with an open, transparent algorithm
Supports any species, chemistry, and sequencer: Handles diverse experimental designs, including UMI-enabled and single-cell datasets
In short, Platforma is the only solution designed to accelerate discovery without compromise, enabling teams to move from raw data to actionable leads faster, securely, and with complete confidence.